Renal function after liver transplantation: Calcineurin inhibitor nephrotoxicity

被引:35
作者
Ziolkowski, J
Paczek, L
Senatorski, G
Niewczas, M
Oldakowska-Jedynak, U
Wyzgal, J
Sanko-Resmer, J
Pilecki, T
Zieniewicz, K
Nyckowski, P
Patkowski, W
Krawczyk, M
机构
[1] Med Univ Warsaw, Dept Immunol Transplant Med & Internal Dis, Inst Transplantat, Warsaw, Poland
[2] Med Univ Warsaw, Dept Gen Transplantat & Liver Surg, Warsaw, Poland
关键词
D O I
10.1016/S0041-1345(03)00786-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Renal failure, mainly due to calcineurin inhibitor (CNI) nephrotoxicity, is the most common complication following orthotopic liver transplantation (ltx). The aim of this study was to evaluate the incidence and course of renal failure in adult ltx patients. Severe acute renal failure in early postoperative period due to impaired hemodynamics and CNI nephrotoxicity, occurred in 14 patients, 3 of whom required dialysis. The creatinine clearance after ltx showed a tendency to decrease, but there was no statistically significant difference (P > .05) in the change in serum creatinine clearance levels between patients treated with tacrolimus (TAC) versus Cyclosporine (CsA) during the first 2 years of follow-up. Fourteen patients required conversion of their regimen because of CNI nephrotoxicity namely, dose reduction (n = 7) or discontinuation of CNI therapy with the replacement by mycophenolate mofetil (MMF) (n = 5) or SRL (n = 5). Dose reduction or CNI withdrawal significantly improved the creatinine clearance (P < .05) without affecting lives graft function. No episode of acute rejection was observed after conversion. Neither conversion of CsA to TAC nor the reverse maneuver significantly influenced the serum creatinine level (P > .05). Reduction of the CNI dose or CNI discontinuation or replacement with MMF or SRL in patients with stable liver but impaired renal function is safe, resulting in a significant improvement in renal function.
引用
收藏
页码:2307 / 2309
页数:3
相关论文
共 14 条
[1]  
ARROYO V, 1993, TRANSPLANT P, V25, P1734
[2]  
Bilbao I, 1998, CLIN TRANSPLANT, V12, P123
[3]   Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation [J].
Chen, JWC ;
Pehlivan, M ;
Gunson, BK ;
Buckels, JA ;
McMaster, P ;
Mayer, D .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1507-1510
[4]  
Eckhoff DE, 1998, TRANSPLANTATION, V65, P180
[5]  
GOLDMAN L, 2000, CECIL TXB MED, P98
[6]   End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy - Risk of development and treatment [J].
Gonwa, TA ;
Mai, ML ;
Melton, LB ;
Hays, SR ;
Goldstein, RM ;
Levy, MF ;
Klintmalm, GB .
TRANSPLANTATION, 2001, 72 (12) :1934-1939
[7]  
HALLER M, 1992, TRANSPLANT P, V24, P2704
[8]   Long-term survival after liver transplantation in 4,000 consecutive patients at a single center [J].
Jain, A ;
Reyes, J ;
Kashyap, R ;
Dodson, F ;
Demetris, AJ ;
Ruppert, K ;
Abu-Elmagd, K ;
Marsh, W ;
Madariaga, J ;
Mazariegos, G ;
Geller, D ;
Bonham, CA ;
Gayowski, T ;
Cacciarelli, T ;
Fontes, P ;
Starzl, TE ;
Fung, JJ .
ANNALS OF SURGERY, 2000, 232 (04) :490-498
[9]   Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial [J].
O'Grady, JG ;
Burroughs, A ;
Hardy, P ;
Elbourne, D ;
Truesdale, A .
LANCET, 2002, 360 (9340) :1119-1125
[10]   Late mortality after orthotopic liver transplantation [J].
Rabkin, JM ;
de la Melena, V ;
Orloff, SL ;
Corless, CL ;
Rosen, HR ;
Olyaei, AJ .
AMERICAN JOURNAL OF SURGERY, 2001, 181 (05) :475-479